The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas-Reference-Cited by-同舟云学术

The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas

Published:2018-09-11 Issue:21 Volume:124 Page:4241-4247
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

DuBois Steven G.¹,Laetsch Theodore W.²,Federman Noah³,Turpin Brian K.⁴,Albert Catherine M.⁵,Nagasubramanian Ramamoorthy⁶,Anderson Megan E.⁷,Davis Jessica L.⁸,Qamoos Hope E.⁹,Reynolds Mark E.⁹,Cruickshank Scott⁹,Cox Michael C.⁹,Hawkins Douglas S.⁵,Mascarenhas Leo¹⁰,Pappo Alberto S.¹¹

Affiliation:

1. Pediatric Hematology/Oncology, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center; Harvard Medical School; Boston Massachusetts

2. Department of Pediatrics; University of Texas Southwestern Medical Center/Children’s Health; Dallas Texas

3. Department of Pediatrics; University of California at Los Angeles; Los Angeles California

4. Cancer and Blood Diseases Institute; Cincinnati Children’s Hospital Medical Center; Cincinnati Ohio

5. Department of Pediatrics, Seattle Children’s Hospital, Fred Hutchinson Cancer Research Center; University of Washington; Seattle Washington

6. Department of Pediatrics; Nemours Children’s Hospital; Orlando Florida

7. Department of Orthopedic Surgery; Boston Children’s Hospital, Harvard Medical School; Boston Massachusetts

8. Department of Pathology; Oregon Health and Science University; Portland Oregon

9. Loxo Oncology Inc; South San Francisco California

10. Department of Pediatrics, Children’s Hospital Los Angeles, Keck School of Medicine; University of Southern California; Los Angeles California

11. Department of Oncology; St Jude Children’s Research Hospital; Memphis Tennessee

Funder

Loxo Oncology

Alex's Lemonade Stand Foundation for Childhood Cancer

National Center for Advancing Translational Sciences

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.31701/fullpdf

Reference9 articles.

1. The neurotrophin family of neurotrophic factors: an overview;Skaper;Methods Mol Biol,2012

2. Infantile NTRK-associated mesenchymal tumors;Davis;Pediatr Dev Pathol,2018

3. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children;Drilon;N Engl J Med,2018

4. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: a multicentre, open-label, phase 1 study;Laetsch;Lancet Oncol,2018

5. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1);Eisenhauer;Eur J Cancer,2009

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Healthcare decision-making for tumour-agnostic therapies in Europe: lessons learned;Drug Discovery Today;2024-07

2. Agnostic drug development revisited;Cancer Treatment Reviews;2024-07

3. Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study);ESMO Open;2024-05

4. Characterization of the malignant cells and microenvironment of infantile fibrosarcoma via single-cell RNA sequencing;Translational Pediatrics;2024-04

5. Opportunity in Complexity: Harnessing Molecular Biomarkers and Liquid Biopsies for Personalized Sarcoma Care;Seminars in Radiation Oncology;2024-04